1. Dotarem dossier France 1989
2. Data on File
3. USA PI as of August 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204781s000lbl.pdf
4. de Kerviler E et al. Invest Radiol. 2016 Sep;51(9):544-51
5. Port M et al. Biometals (2008) 21:469–490
6. Dotarem: Summary of product specifications
7. Neiss AC et al. Efficacy and safety of DOTA-Gd from a European multicenter survey. Preliminary results on 4,169 cases. 1991; Rev Im Med 3:383–7.
8. Briand Y et al. Efficacy and safety of the macrocyclic complex Gd-DOTA in children: results of a multicentre study. Proceedings of the 29th Congress of the European Society of Pediatric Radiology. 1992; 128.
9. Ishiguchi T & Takahashi S. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. Drugs R D. 2010;10(3):133-45.
10. Emond S & Brunelle F. Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions. Pediatr Radiol. 2011 Nov;41(11):1401-6.
11. Maurer M et al. Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients. Eur J Radiol. 2012 May;81(5):885-90.
12. Soyer et al. Observational Study on the Safety Profile of Gadoterate Meglumine in 35,499 Patients: The SECURE Study. J. Magn. Reson. Imag. 2017; 45, 988-997
13. de Kerviler et al. Adverse Reactions to Gadoterate Meglumine Review of Over 25 Years of Clinical Use and More Than 50 Million Doses. Investigative Radiology. September 2016; 51, 9, 544-551
14. Radbruch A et al. Radiology. 2015 Jun;275(3):783-97.
15. Radbruch A et al. Invest Radiol. 2016 Nov;51(11):683-90.
16. Eisele P et al. Medicine (Baltimore). 2016 Sep;95(39):e4624.
17. Radbruch A et al. Radiology. 2017 Mar;282(3):699-707.
18. Radbruch A et al. Radiology. 2017 Jun;283(3):828-836.
19. Balassy C et al. Pediatr Radiol (2015) 1836
20. Maurer M et al. European Journal of Radiology 81 (2012) 887,889
21. Guerbet - Une aventure de plus d'un siècle au service de la Santé

DOTAREM 0.5 mmol/mL, solution for injection. **Composition:** For 100 mL of solution: active ingredient: Gadoteric Acid 27.932 g corresponding to: DOTA 20.246 g corresponding to gadolinium oxide 9.062 g. **Indications (*):** Medicinal product for diagnostic use only: Magnetic Resonance Imaging for cerebral and spinal disease, diseases of the vertebral column, and other whole-body pathologies (including angiography). Dotarem should be used only when diagnostic information is essential and not available with unenhanced magnetic resonance imaging (MRI). **Posology and method of administration:** The recommended dose is 0.1 mmol/kg, i.e. 0.2 mL/kg in adults and children. The lowest dose that provides sufficient enhancement for diagnostic purposes should be used. The dose should be calculated based on the patient's body weight, and should not exceed the recommended dose per kilogram of body weight detailed in this section. In angiography, depending on the results of the examination being performed, a second injection may be administered during the same session if necessary. Angiography with Gadoteric acid is not recommended in children (0-18 years). In Encephalic and spinal MRI, in some exceptional cases, as in the confirmation of isolated metastasis or the detection of leptomeningeal tumours, a second injection of 0.2 mmol/kg may improve tumor characterisation and facilitate therapeutic decision making. For patients with impaired renal function and paediatric population (0-18 years) more than one dose should not be used during a scan, injections should not be repeated unless the interval between injections is at least 7 days. The product must be administered by strict intravenous injection. Depending on the amount of gadoteric acid to be given to the child, it is preferable to use gadoteric acid vials with a single use syringe of a volume adapted to this amount in order to have a better precision of the injected volume. In neonates and infants the required dose should be administered by hand. **Contraindications:** Hypersensitivity to gadoteric acid, to meglumine or to any medicinal products containing gadolinium. **Special warnings and precautions for use:** Dotarem must not be administered by subarachnoid (or epidural) injection. The usual precaution measures for MRI examination should be taken such as exclusion of patients with pacemakers, ferromagnetic vascular clips, infusion pumps, nerve stimulators, cochlear implants or suspected intracorporal metallic foreign bodies, particularly in the eye. **General particulars corresponding to all gadolinium contrast agents:** All gadolinium based contrast media can cause minor or major hypersensitivity reactions that can be life-threatening. These can occur immediately (within 60 minutes) or be delayed (within 7 days) and are often unpredictable. Because of the risk of major reactions, emergency resuscitation equipment should be available for immediate use. Hypersensitivity reactions can be aggravated in patients on betablockers and particularly in the presence of bronchial asthma. These patients may be refractory to standard treatment of hypersensitivity reactions with beta agonists. Impaired renal function: Prior to administration of gadoteric acid, it is recommended that all patients are screened for renal dysfunction by obtaining laboratory tests. There have been reports of Nephrogenic Systemic Fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with severe renal impairment (GFR < 30 ml/min/1.73 m2). As there is a possibility that NSF may occur with Dotarem, it should only be used in these patients after careful consideration. CNS disorders: As with other contrast agents containing gadolinium, special precautions should be taken in patients with a low seizure threshold. Precautionary measures, e.g. close monitoring, should be taken. All equipment and drugs necessary to counter any convulsions which may occur must be made ready for use beforehand. **Interactions with other medicinal products and other forms of interaction:** No interactions with other medicinal products have been observed. Formal drug interaction studies have not been carried out. **Fertility, pregnancy and lactation:** Gadoteric acid should not be used during pregnancy unless the clinical condition of the woman requires use of gadoteric acid. Continuing or discontinuing breast feeding for a period of 24 hours after administration of gadoteric acid, should be at the discretion of the doctor and lactating mother. **Effects on ability to drive and use machines:** No studies on the effects on the ability to drive and use machines have been performed. Ambulant patients while driving vehicles or operating machinery should take into account that nausea may incidentally occur. **Undesirable effects:** Uncommon (≥1/1000 to <1/100); hypersensitivity, headache, dysgeusia, dizziness, somnolence, paraesthesia (including burning sensation), hypotension, hypertension, nausea, abdominal pain, rash, feeling hot, feeling cold, asthenia, injection site reactions (extravasation, pain, discomfort, oedema, inflammation, coldness). Rare (≥1/10 000 to <1/1 000): anxiety, presyncope, eyelid edema, palpitations, sneezing, throat tightness, vomiting, diarrhea, salivary hypersecretion, Urticaria, pruritus, hyperhidrosis, chest pain, chills. Very rare (<1/10 000): anaphylactic reaction, anaphylactoid reaction, agitation, coma, convulsion, syncope, tremor, parosmia, conjunctivitis, ocular hyperaemia, vision blurred, lacrimation increased, tachycardia, cardiac arrest, arrhythmia, bradycardia, flushing, pallor, vasodilatation, hot flush, cough, dyspnoea, nasal congestion, respiratory arrest, bronchospasm, throat irritation, laryngospasm, pharyngeal oedema, dry throat, pulmonary oedema, erythema, angioedema, eczema, muscle cramps, muscular weakness, back pain, arthralgia, malaise, chest discomfort, pyrexia, face oedema, injection site necrosis (in case of extravasation), phlebitis superficial, decreased oxygen saturation. Not known: nephrogenic systemic fibrosis. **Overdose:** Gadoteric acid can be removed by haemodialysis. However there is no evidence that haemodialysis is suitable for prevention of nephrogenic systemic fibrosis. **Please note:** The peel-off tracking label on the vials or syringes should be stuck onto the patient record to enable accurate recording of the gadolinium contrast agent used. The dose used should also be recorded. If electronic patient records are used, the name of the product, the batch number and the dose should be entered into the patient record. **Pharmacological properties**: Pharmacotherapeutic group: paramagnetic contrast media for MRI, ATC code: V08CA02. **Presentation (*):** 5, 10, 15, 20, 60 & 100 mL in vial (glass) and 10, 15 & 20 mL in a prefilled syringe (glass). **Marketing authorization holder: (*) Information:** Guerbet - BP 57400 - F-95943 Roissy CdG cedex – FRANCE. Tel: 33 (0) 1 45 91 50 00. **Date of revision of this document**: February 2018

For current and complete prescribing information refer to the package insert and/or contact your local Guerbet organization.

(*) Indications, presentations and marketing authorization holder may differ from country to country.

Reporting of suspected adverse reactions is important as it helps to continuously assess the benefit-risk balance. Therefore, Guerbet encourages you to report any adverse reactions to your health authorities or to our local Guerbet representative.

Guerbet

P19 120 DOT - July 2019 annapurna8000

Guerbet

FOR MORE THAN A CENTURY, **GUERBET CONTRIBUTES TO THE BIG PHARMACEUTICAL DISCOVERIES** IN DIAGNOSTIC PER IMAGING

Our key values:

ACHIEVE | COOPERATE | CARE | INNOVATE

1901
Start of the life of Guerbet [14]

More than **200 people work in the R&D**.
In 10 years Guerbet has invested **393M€ in R&D**

2700 employees worldwide
+ **60 distributors**

Guerbet is **a pioneer** in the contrast-agent field, with more than **90 years of experience** and a **leader in medical imaging** worldwide.

It offers **a comprehensive range** of pharmaceutical products, medical devices and services for diagnostic and interventional imaging.

8% of the revenue and more than **200 employees** are **dedicated to R&D**.
Guerbet (GBT) is listed on Euronext Paris and generated 790 million in 2018 revenue.

Our affiliates:

EMEA (Europe, Middle East and Africa), Guerbet is one of the leaders in MRI (13 affiliates)

America, Guerbet is well established in latin America and expands its presence in the North American market (9 affiliates)

Asia-Pacific, the dynamic nature of the Asia-Pacific market offers the Group substantial potential for growth (6 affiliates)



Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Portugal, South Africa, Spain, Switzerland, Turkey, United Kingdom
Argentina, Brazil, Canada, Chile, Colombia, Mexico, Panama, Puerto Rico, USA
Australia, China, Hong Kong (Asia-Pacific), Japan, South Korea, Taiwan

DOTAREM®

Gadoteric acid

GUERBET & **DOTAREM®**: A JOURNEY

MORE THAN 30 YEARS

30

DOTAREM®

gadoteric acid

Guerbet | COMMITTED

DOTAREM®

Gadoteric acid

LAUNCHED IN 1989, DOTAREM® IS THE **FLAGSHIP PRODUCT** OF GUERBET.

A LEADING CONTRAST MEDIA WORLDWIDE

1ST

The **first high stability macrocyclic GBCA*** in the market [1]

30 YEARS

30 years of experience

91 MILLION

More than **91 million doses** injected globally [2]



- Available in more than **70 countries**
- **No confirmed unconfounded cases of Nephrogenic Systemic Fibrosis** (NSF) [3,4]
- **A high kinetic stability** provided by the macrocyclic structure [5]
- **Low rate of adverse events** in adults & children [6-13]
- **No visible brain hyperintensities** related to dechelated Gd following repeated injections [14-18]
- Optimal performance in **adults and children diagnoses** [19-20]

Indications: Medicinal product for diagnostic use only: Magnetic Resonance Imaging for cerebral and spinal disease, diseases of the vertebral column, and other whole-body pathologies (including angiography). Dotarem should be used only when diagnostic information is essential and not available with unenhanced magnetic resonance imaging (MRI).

*gadolinium-based contrast agent **Indications may differ from country to country.

DOTAREM® is available in vials and prefilled syringes

For more information please visit **www.guerbet.com**

KEY DATES IN DOTAREM® HISTORY

1987 — **Guerbet bought Simafex** (ex Pierre Fabre) for the production of Dotarem® [21]

1989 — **Launch of Dotarem®** First launch in France, Switzerland, Brazil, Benelux, and Portugal [21]

2013 — **Marketing authorization and first patient injected in the USA** [21]

2019 — **91 million** doses injected [2] with **zero unconfounded cases of NSF** [3] and **no visible brain hyperintensities**

DOTAREM® CONTINUES ITS JOURNEY...

MORE THAN 30 YEARS

DOTAREM® gadoteric acid

Worldwide Marketing Authorization for DOTAREM®

1989: France, Luxembourg, Belgium

1990: Switzerland

1991: Portugal

1994: Argentina

1995: Republic of Korea, Sweden, Finland

1996: Greece, Denmark, Italy, Tunisia, Ireland, Morocco, Mexico, United Kingdom, Peru, Chile, Singapore, Hong Kong

1997: Norway, Lebanon, Israel, South Africa, Czech Republic, New Zealand, Austria

1998: Turkey, Colombia, Russian Federation, Spain, China

1999: Taiwan, Algeria, Slovenia, Thailand, El Salvador, Kuwait

2000: Japan, Philippines, Australia

2001: Saudi Arabia, Malaysia, Brazil

2002: Vietnam, Venezuela, Egypt

2003: Hungary, Germany, India, The Netherlands

2004: Bosnia and Herzegovina

2005: Iran

2006: Croatia, Romania

2007: Bolivia

2008: Costa Rica

2009: Paraguay, Senegal, Ivory Coast

2010: State of United Arab Emirates, Guatemala, Jordan

2011: Ecuador, Indonesia

2012: Cameroon

2013: Estonia, United States of America

2014: Slovakia, Lithuania, Latvia, Cyprus, Nepal, Poland, Bulgaria

2015: Cambodia

2016: Mongolia, Canada

2018: Burkina Faso, Panama, Pakistan

2019: Uruguay